Finally we showed that the integrin-targeted dual pan- PI3K/BRD4 inhibitor, SF1126, potently blocked tumor growth and tumor angiogenesis along with decreasing MYCN mRNA and protein in subcutaneous neuroblastoma xenografts. Here, BRD4 is linked to neoplasm.